- News Library
- Servier Medical Art
- Partnering & Licensing
One of Servier's guiding principles is that our research should make a significant contribution to medical progress. This principle drives our commitment to data-sharing initiatives, which we believe is an important way forward in clinical research to enhance global public health.
With research programs ongoing in 6 major fields of medicine, Servier stands as a major player in pharmaceutical research. Collaboration between industry and external medical and scientific research partners is essential to progress in clinical research and drug development. This collaboration can only be successful if it is transparent, responsible, and fully compliant with regulatory requirements, and if it completely respects patient rights. Read more ...
As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Servier fully supports the objectives of the Disclosure Code. We believe this Code will contribute to provide a better insight on the long established relationship between healthcare professionals and pharmaceutical companies for the improvement of patient care.
The Disclosure Initiative is part of our company’s commitment to transparency.
What is the EFPIA Disclosure Code about?
Healthcare professionals and pharmaceutical companies collaborate on many projects essential for research, development and access to the market of new medicines. These interactions are complex. This is why, day after day; communication initiatives are developed to improve transparency.
Read more ...
Servier, founded in 1954, is the first French independent pharmaceutical group. We are present in 148 countries, with more than 21 200 employees, including close to 3000 in R&D.